Japan's Otsuka to buy Astex Pharma for about $900 million: Nikkei
(Reuters) - Japanese drugmaker Otsuka Holdings Co will buy Astex Pharmaceuticals Inc for about 90 billion yen ($900 million) to tap the cancer drugs the U.S. company is developing, the Nikkei said. (link.reuters.com/hed82v)
Shares of Astex, which has a market capitalization of $634.2 million as of Tuesday close, rose as much as 41 percent to a nine-year high of $9.39 on the Nasdaq.
Astex, whose only approved drug, Dacogen, treats a blood disorder called myelodysplastic syndromes, is developing drugs to treat prostate, lung and ovarian cancer.
Otsuka and Astex were not immediately available for comments.
($1 = 99.5350 Japanese yen)
(Reporting By Vrinda Manocha in Bangalore; Editing by Don Sebastian)
NEW YORK - Earnings season shifts into high gear next week, and with nearly one-third of S&P 500 names set to post results, investors hope the news provides a catalyst to buy stocks and leave the market's recent weakness in the dust.
- The troubles at BlackBerry Ltd, which fired more than half its staff and lost more than 90 percent of its market value as consumers shunned its smart phones, might have spelled disaster for the company's hometown of Waterloo, Ontario. Instead, there are hot sports cars in the streets and new companies filling the refurbished office buildings. | Video
BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.